From surgery to systemic therapy in von Hippel-Lindau disease: insights from extended follow-up of LITESPARK-004

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Translational Andrology and Urology

• Publication date

  2025-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.21037/tau-2025-637PMID 41368258PMCID 12683487
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.

  2025cited by this paper
• Human leukocyte antigen sensitization from red cell transfusions: Rate and risk factors in renal and nonrenal patients requiring transfusion.

  2025cited by this paper
• Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study.

  2025cited by this paper
• Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel–Lindau (VHL) disease-associated haemangioblastoma

  2025cited by this paper
• Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease.

  2025cited by this paper
• Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.

  2025influential reference
• Disease Monitoring and Treatment Patterns of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States.

  2025cited by this paper
• Effect of erythropoietin-stimulating agent use on belzutifan antitumor activity in patients with VHL disease–associated renal cell carcinoma: Post hoc analysis of the LITESPARK-004 study.

  2024cited by this paper
• Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.

  2024cited by this paper
• Advances in Molecular Mechanisms of Kidney Disease: Integrating Renal Tumorigenesis of Hereditary Cancer Syndrome

  2024cited by this paper
• Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

  2024influential reference
• Endolymphatic Sac Tumors Associated With von Hippel–Lindau: A Case Report Highlighting Opportunity for Novel Orphan Drug Therapy

  2024cited by this paper
• Oral HIF-2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.

  2024cited by this paper
• Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.

  2024cited by this paper
• LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.

  2023cited by this paper
• Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.

  2022cited by this paper
• FDA Approval Summary: Belzutifan for von Hippel-Lindau disease associated tumors.

  2022cited by this paper
• The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?

  2022cited by this paper
• Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.

  2021cited by this paper
• Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.

  2021influential reference
• Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.

  2019cited by this paper
• Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

  2018cited by this paper
• Renal Cell Carcinoma in von Hippel–Lindau Disease—From Tumor Genetics to Novel Therapeutic Strategies

  2018cited by this paper
• von Hippel-Lindau disease: Diagnosis and factors influencing disease outcome.

  2018cited by this paper
• Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective.

  2016cited by this paper
• Renal tumor size is an independent prognostic factor for overall survival in von Hippel–Lindau disease

  2014cited by this paper
• Current Status of Use of Erythropoietic Agents in Cancer Patients

  2014cited by this paper
• Functional significance of erythropoietin in renal cell carcinoma

  2013cited by this paper
• Life expectancy in hereditary cancer predisposing diseases: an observational study

  2012cited by this paper
• Systemic VHL gene functions and the VHL disease

  2012cited by this paper
• What is the European Medicines Agency?

  2012cited by this paper
• Erythropoietin or darbepoetin for patients with cancer.

  2012cited by this paper
• von Hippel–Lindau disease: A clinical and scientific review

  2011cited by this paper
• clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

  2010cited by this paper
• Erythropoietin or darbepoetin for patients with cancer.

  2006cited by this paper

• No citing papers are available for this paper.